All news

Tenax Therapeutics faces securities fraud lawsuit after trial failure

Alpha Vantage · PR Newswire · · AI-summarised by FinFlash

Tenax Therapeutics faces a securities class action lawsuit alleging management overstated the commercial and regulatory prospects of its drug candidate TNX-103. The legal action follows a Phase 3 trial failure that caused the company stock to plunge nearly 90 percent. For investors, the pending litigation adds substantial legal and financial uncertainty.

Read original source

TENX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.